With roots in journalism at Reuters News in Hong Kong and a career spanning global health, biotech, and nonprofit advocacy, Alexandra Hoegberg is a master of message and mission. Her strategic communications work has influenced policy, built reputations, and connected stakeholders across borders and sectors. She is now a fierce entrepreneur and consultant – and recently joined the Ventures Accelerated team. 

Founder Helena Strigård interviews her on the driving force behind that sharp pen of hers! 

JPM Healthcare Week is no longer about being seen: it’s about being ready. In this piece, conversations with OnDosis and Treos Bio reveal how strategic clarity, credible data, and execution maturity now define meaningful engagement at JPM. From personalized drug delivery to globally aligned clinical development, the article highlights what it takes to show up with intent in today’s capital-constrained market.

In this Corporate Insights, Julie Ames, President and CEO of The Cambridge Group, argues that JP Morgan Healthcare Week is not about visibility, but reputation. Drawing on deep experience advising life science leaders, she explains how JPM has become a high-signal stress test where strategic clarity, disciplined storytelling, and leadership judgment matter more than volume or hype. The piece outlines how companies are evaluated before, during, and after the week, and why those that arrive prepared build momentum long after JPM ends.

As the global life science community gathers for JPM Healthcare Conference Week, attention turns to where capital will flow next. Drawing on a recent Economist analysis, Anders Månsson examines Stockholm’s emergence as a European “capital of capital” — driven by stability, proximity between science and finance, and an innovation-led growth model.

Meet Tracy Humphries, one of our Accelerators, who shares her perspective on the evolving B2B buyer journey. Drawing on 25+ years in life sciences, she discusses why trust, lifecycle marketing, and close alignment between marketing and sales are essential for engaging customers in a digital and AI-driven world.

At a panel discussion organized by EY Parthenon, investors and industry leaders examined the tightening funding landscape for early-stage Nordic life science companies. The message was clear: strong science alone is no longer enough. Success now requires strategic clarity, disciplined execution, early investor engagement, and partnerships that build credibility in a more selective market.

Busyness creates motion, but impact requires direction. In this editorial, Anders Månsson challenges the culture of constant activity and argues for a sharper focus on judgment, clarity, and purposeful leadership. Because real results come from what truly matters, not from doing more.

One of our Accelerators, Rebeca Varela Lores, shares her journey from biomedical sciences to bioentrepreneurship and how her international experiences have shaped a global outlook on innovation. Now part of the Ventures Accelerated team, Rebeca reflects on lessons from early-stage ventures, the excitement of working at the intersection of science and strategy, and the mindset needed to turn bold ideas into impact.

The 2025 Nobel Prize in Physiology or Medicine honors Dr. Fred Ramsdell, Dr. Mary E. Brunkow, and Dr. Shimon Sakaguchi for discoveries that transformed our understanding of the immune system. In exclusive interviews, Ventures Accelerated speaks with Nobel laureate Fred Ramsdell, Dr. Karin Rosén of Diamyd Medical, Sarah Fredriksson of Aqilion, and Dr. Patricia Beckmann to explore how decades of research are now translating into new treatments for autoimmune and inflammatory diseases.

What can this year’s Nobel Prize in Economics teach biotech? In this editorial, Anders Månson dives into the laureates’ ideas on innovation-driven growth and creative destruction to unpack today’s biotech “funding winter.” He challenges the industry’s growing risk aversion and explores how rekindling bold innovation could reignite the sector’s momentum.